Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-isobutyl-1-methylxanthine (IBMX) is a synthetic xanthine derivative widely used in research as a non-selective, non-specific inhibitor of cyclic nucleotide phosphodiesterases (PDEs), particularly those that degrade cAMP and cGMP. By inhibiting these enzymes, IBMX increases intracellular levels of cAMP and cGMP, leading to activation of downstream signaling pathways. It also acts as an antagonist at adenosine receptors. These actions make it a valuable tool in studies involving signal transduction, melanogenesis induction, oocyte maturation arrest, neuroprotection, cardiovascular function modulation, and smooth muscle relaxation. IBMX has no approved pharmaceutical indications but is extensively used in laboratory settings for mechanistic studies related to metabolism, cognition enhancement research, respiratory disease models (due to bronchodilatory effects), and sports science[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-isobutyl-1-methylxanthine.